HC Wainwright Expects Stronger Earnings for Pyxis Oncology

Pyxis Oncology, Inc. (NASDAQ:PYXS) – HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for shares of Pyxis Oncology in a research note issued to investors on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.29) for the quarter, up from their previous estimate of ($0.38). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.17) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at $0.24 EPS.

Separately, Royal Bank of Canada restated an “outperform” rating and set a $8.00 target price on shares of Pyxis Oncology in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.20.

Pyxis Oncology Trading Up 8.0 %

Shares of NASDAQ:PYXS opened at $1.21 on Friday. Pyxis Oncology has a 1-year low of $0.99 and a 1-year high of $6.18. The firm has a market capitalization of $74.52 million, a PE ratio of -1.17 and a beta of 1.11. The business’s 50 day moving average is $1.33 and its 200-day moving average is $2.36.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.01. The firm had revenue of $16.15 million for the quarter.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Ridgeback Capital Investments L.P. bought a new position in shares of Pyxis Oncology during the 4th quarter worth approximately $560,000. ProShare Advisors LLC bought a new position in Pyxis Oncology in the 4th quarter valued at $26,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Pyxis Oncology in the 4th quarter valued at $228,000. Millennium Management LLC raised its position in Pyxis Oncology by 53.8% in the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company’s stock valued at $4,650,000 after purchasing an additional 1,043,228 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in Pyxis Oncology by 57.2% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company’s stock valued at $939,000 after purchasing an additional 219,100 shares during the last quarter. Institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.